<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-XJIERMQ1</identifier><date>1996</date><creator>Štabuc, Borut</creator><relation>documents/doc/X/URN_NBN_SI_doc-XJIERMQ1_001.pdf</relation><relation>documents/doc/X/URN_NBN_SI_doc-XJIERMQ1_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 5-19</format><identifier identifier_type="COBISSID_HOST">8663001</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-XJIERMQ1</identifier><language>slv</language><publisher>Onkološki inštitut</publisher><source>Novosti v sistemskem zdravljenju in pri zdravljenju kronične bolečine</source><rights>InC</rights><subject language_type_id="slv">Antibodies, monoclonal</subject><subject language_type_id="slv">Biological response modifiers</subject><subject language_type_id="slv">Growth substances</subject><subject language_type_id="slv">Immunotherapy</subject><subject language_type_id="slv">Interferons</subject><subject language_type_id="slv">Interleukin-2</subject><subject language_type_id="slv">Neoplasms</subject><subject language_type_id="slv">Therapy</subject><subject language_type_id="slv">Tumor necrosis factor</subject><title>Zdravljenje raka z modifikatorji biološkega odziva</title></Record>